Toxicity and Tolerance of Concurrent Docetaxel with Radiotherapy in Cisplatin Ineligible Head and Neck Cancer Patients. (Record no. 83071)

000 -LEADER
fixed length control field 02761nab a22002777a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 180606b2018 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Simha V
245 ## - TITLE STATEMENT
Title Toxicity and Tolerance of Concurrent Docetaxel with Radiotherapy in Cisplatin Ineligible Head and Neck Cancer Patients.
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc 2018
300 ## - PHYSICAL DESCRIPTION
Extent
500 ## - GENERAL NOTE
General note Address for Corresponding Author:
520 ## - SUMMARY, ETC.
Summary, etc e18022

Background: Docetaxel can be administered in several situations like low creatinine clearance or pre existing grade 3-4 ototoxicity, where cisplatin is contraindicated. In this analysis, we present our data on toxicity and tolerance to docetaxel based chemoradiation in cisplatin ineligible patients. Methods: Patients who underwent docetaxel based chemoradiation between January 2015 to April 2017 for locally advanced head and neck cancer, either in radical or adjuvant setting in the Department of Medical Oncology at Tata memorial Hospital were selected for this analysis. SPSS version 16 was used for analysis. They received Docetaxel 15mg/m2 intravenously in a weekly schedule. Descriptive statistics is used to present the data. Continuous variables were described in terms of median and interquartile range while categorical variables were described in terms of percentages with 95%CI Results: Nineteen patients were identified and the median age of the cohort was 58 years ( range 41-71 years). The most common site of primary was oral cavity (n = 9, 47.4%). Sixteen patients (84.2%) had stage IV disease and 3 patients (15.8%) had stage 3 disease. The intent of chemoradiation was radical in 12 (63.9%) patients and adjuvant in 7 (36.1%) patients. Any grade 3 or above adverse events were seen in 12 patients (63.2%). The most common grade 3 or above adverse events observed were mucositis and hyponatremia in 9 patients (47.4%) each. Compliance to radiation and docetaxel was observed 16 (84.2%) and 15 patients (78.9%) respectively. The median progression free survival was 10.3 months (95%CI 2.3-18.3 months) while the median overall survival was 25.3 months ( 95%CI 6.7-43.9 months). Conclusions: Docetaxel based chemoradiation is a feasible and well tolerated regimen in cisplatin ineligible patients and needs further testing in large randomized studies to prove its worth.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Docetaxel
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Chemoradiation
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Ototoxicity
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Patil V
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Noronha V
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Talreja V
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Dhumal S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Chandrasekharan A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Shrirangwar S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Prabhash K
773 ## - HOST ITEM ENTRY
Main entry heading Journal of Clinical Oncology
Place, publisher, and date of publication Alexandria, VA : American Society of Clinical Oncology, 2018
Relationship information Vol. 36, Suppl_15
International Standard Serial Number 0732-183X
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
Dept Medical Oncology
Corporate name TMC
Article Type Conference Abstract
Country type International
Added Entry TMH
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Item type Articles
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent location Current location Date acquired Barcode Date last seen Koha item type
          Tata Memorial Hospital Tata Memorial Hospital 2018-06-06 AR19011 2018-06-06 Articles

Powered by Koha